JP2022151814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022151814A5 JP2022151814A5 JP2022047297A JP2022047297A JP2022151814A5 JP 2022151814 A5 JP2022151814 A5 JP 2022151814A5 JP 2022047297 A JP2022047297 A JP 2022047297A JP 2022047297 A JP2022047297 A JP 2022047297A JP 2022151814 A5 JP2022151814 A5 JP 2022151814A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- polysorbate
- pharmaceutical composition
- buffer
- poloxamer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 8
- 229920001983 poloxamer Polymers 0.000 claims 8
- 229960000502 poloxamer Drugs 0.000 claims 8
- -1 polyoxyethylene Polymers 0.000 claims 8
- 229920000136 polysorbate Polymers 0.000 claims 8
- 229950008882 polysorbate Drugs 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000000872 buffer Substances 0.000 claims 7
- 150000002016 disaccharides Chemical class 0.000 claims 7
- 230000007935 neutral effect Effects 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 4
- 229920001451 polypropylene glycol Polymers 0.000 claims 4
- 229920000053 polysorbate 80 Polymers 0.000 claims 4
- 229940068968 polysorbate 80 Drugs 0.000 claims 4
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 239000007979 citrate buffer Substances 0.000 claims 3
- 102000056929 human IDUA Human genes 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 125000000185 sucrose group Chemical group 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000002132 lysosomal effect Effects 0.000 claims 2
- 102000007238 Transferrin Receptors Human genes 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021049485 | 2021-03-24 | ||
| JP2021049485 | 2021-03-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022151814A JP2022151814A (ja) | 2022-10-07 |
| JP2022151814A5 true JP2022151814A5 (enExample) | 2025-04-01 |
Family
ID=83395731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022047297A Pending JP2022151814A (ja) | 2021-03-24 | 2022-03-23 | 安定な水性医薬組成物又は凍結乾燥医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240165258A1 (enExample) |
| EP (1) | EP4311555A4 (enExample) |
| JP (1) | JP2022151814A (enExample) |
| KR (1) | KR20230160848A (enExample) |
| CN (1) | CN116997352A (enExample) |
| AU (1) | AU2022245592A1 (enExample) |
| BR (1) | BR112023019201A2 (enExample) |
| CA (1) | CA3214463A1 (enExample) |
| MX (1) | MX2023011087A (enExample) |
| WO (1) | WO2022202947A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117279665A (zh) * | 2021-05-12 | 2023-12-22 | Jcr制药股份有限公司 | 黏多糖贮积症i型的治疗用药物组合物 |
| TW202525329A (zh) * | 2023-09-14 | 2025-07-01 | 南韓商綠十字股份有限公司 | 含有α－半乳糖苷酶Ａ融合蛋白的新穎冷凍乾燥製劑 |
| KR20250081554A (ko) * | 2023-11-29 | 2025-06-05 | 주식회사 에스엔바이오사이언스 | 시롤리무스 및 알부민을 포함하는 나노입자, 이를 포함하는 피하투여용 약제학적 조성물 및 이의 제조방법 |
| WO2025229980A1 (ja) * | 2024-05-01 | 2025-11-06 | Ｊｃｒファーマ株式会社 | 凍結乾燥製剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5488034A (en) * | 1993-02-02 | 1996-01-30 | Xoma Corporation | Pharmaceutical composition comprising BPI proteins |
| CN101674805A (zh) * | 2007-05-02 | 2010-03-17 | 诺沃-诺迪斯克保健股份有限公司 | 包括芳香族防腐剂和抗氧化剂的高浓度因子ⅶ多肽制剂 |
| JP6279466B2 (ja) | 2012-04-27 | 2018-02-14 | Ｊｃｒファーマ株式会社 | 新規な発現ベクター |
| CA3048381A1 (en) * | 2016-12-28 | 2018-07-05 | Jcr Pharmaceuticals Co., Ltd. | Lyophilized preparation |
| JOP20190162A1 (ar) * | 2016-12-30 | 2019-06-27 | Biocad Joint Stock Co | تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني |
| WO2019049967A1 (ja) * | 2017-09-07 | 2019-03-14 | Ｊｃｒファーマ株式会社 | 水性医薬組成物 |
| CN117279665A (zh) * | 2021-05-12 | 2023-12-22 | Jcr制药股份有限公司 | 黏多糖贮积症i型的治疗用药物组合物 |
-
2022
- 2022-03-23 CN CN202280022149.2A patent/CN116997352A/zh active Pending
- 2022-03-23 MX MX2023011087A patent/MX2023011087A/es unknown
- 2022-03-23 US US18/283,050 patent/US20240165258A1/en active Pending
- 2022-03-23 EP EP22775729.1A patent/EP4311555A4/en active Pending
- 2022-03-23 AU AU2022245592A patent/AU2022245592A1/en active Pending
- 2022-03-23 WO PCT/JP2022/013755 patent/WO2022202947A1/ja not_active Ceased
- 2022-03-23 CA CA3214463A patent/CA3214463A1/en active Pending
- 2022-03-23 JP JP2022047297A patent/JP2022151814A/ja active Pending
- 2022-03-23 BR BR112023019201A patent/BR112023019201A2/pt unknown
- 2022-03-23 KR KR1020237035015A patent/KR20230160848A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022151814A5 (enExample) | ||
| KR102843708B1 (ko) | 이중특이적 항체 작제물을 포함하는 약제학적 조성물 | |
| TWI721020B (zh) | 一種抗ｐｄ-１抗體製劑及其在醫藥上的應用 | |
| JP2024099682A5 (enExample) | ||
| JP7046088B2 (ja) | 抗ｒｓｖモノクローナル抗体製剤 | |
| JP5877161B2 (ja) | クロストリジウム・ディフィシル感染を予防または抑制するための治療法 | |
| US6403098B1 (en) | Rotavirus vaccine formulations | |
| US6616931B1 (en) | Rotavirus vaccine formulations | |
| JP2024099628A5 (enExample) | ||
| JP2016534052A5 (enExample) | ||
| JP2010511665A5 (enExample) | ||
| JP2009524595A5 (enExample) | ||
| JP7710485B2 (ja) | 抗Ｈｅｒ２抗体薬物コンジュゲートの製剤 | |
| US20210369616A1 (en) | Process for lyophilized pharmaceutical formulations of a therapeutic protein | |
| TW201223541A (en) | Liquid formulations of long acting interferon alpha conjugate | |
| EP0939648B1 (en) | Rotavirus vaccine formulations | |
| JP2019509311A5 (enExample) | ||
| TWI617324B (zh) | 高度濃縮之長效人類生長激素共軛物之液體製劑 | |
| TW201735940A (zh) | 長效人類生長激素共軛物之新穎液體調配物 | |
| JP2020506882A (ja) | 炎症性障害の治療療法 | |
| US20250152706A1 (en) | Compositions for oral delivery of biotherapeutics | |
| JP2022176154A5 (enExample) | ||
| CN115721732A (zh) | 抗体偶联药物的药物组合物、制剂及其制备方法、用途 | |
| JPWO2023081652A5 (enExample) | ||
| JPWO2023064886A5 (enExample) |